In a recent six-month experiment, the effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (Empagliflozin in Non-diabetic Patients With Heart Failure and Reduced Ejection Fraction (EMPA-TROPISM)) done only on non-diabetics (n=84) with HFrEF revealed that the benefits of EMPA extend beyond diabetes, particularly in terms of CV outcomes. The gene discussed is SLC5A2; the disease is heart failure.